Showing results (71-80 of 406) with videos related to

Sort By:
Pageof 41
Bulletin Du Cancer|April 10, 2017
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practicesAnthony Turpin, David Pasquier, Christophe Massard, et al.
Investigational New Drugs|February 18, 2009
Wound healing delay after central venous access following DCF/VEGF-trap therapyCharles Ferté, Christophe Massard, Christian Moldovan, et al.
Bulletin Du Cancer|January 2, 2018
[Atezolizumab (Tecentriq<sup>®</sup>): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]Alice Bernard-Tessier, Clément Bonnet, Pernelle Lavaud, et al.
Expert Review of Molecular Diagnostics|September 24, 2015
Emerging circulating biomarkers in glioblastoma: promises and challengesMehdi Touat, Alberto Duran-Peña, Agusti Alentorn, et al.
Investigational New Drugs|April 28, 2009
Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trialRastislav Bahleda, Christophe Massard, Jean-Charles Soria, et al.
Prostate Cancer and Prostatic Diseases|May 6, 2020
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic reviewRaffaele Ratta, Annalisa Guida, Florian Scotté, et al.
Bulletin Du Cancer|February 7, 2004
[Targeting epidermal growth factor receptor in cancer of the breast]Véronique Diéras, Jean-Yves Pierga, Anne Vincent-Salomon, et al.
Cancer Medicine|September 26, 2022
Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancerMatthieu Delaye, Adrien Rousseau, Mélanie Try, et al.
Clinical Genitourinary Cancer|September 11, 2017
Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave RoussyAnnalisa Guida, Laurence Albiges, Lisa Derosa, et al.
Clinical Genitourinary Cancer|July 17, 2012
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinomaAline Guillot, Antonin Levy, Cécile Pacaut, et al.
Pageof 41